Stryker Launches Surpass Elite Flow Diverter

Stryker recently announced the commercial launch of the Surpass Elite Flow Diverter in the United States, South Korea and Europe. This next-generation device represents a significant advancement in flow diversion, combining an upgraded implant design with a proprietary surface modification for enhanced performance and reduced thrombin generation.

Surpass Elite Flow Diverter introduces BioStealth Surface, a new surface modification developed through a proprietary neutralization process that creates a more thromboresistant cobalt chromium and is backed by both in vitro and in vivo studies.

Surpass Elite Flow Diverter also introduces a fundamentally improved implant design—engineered with a higher braid angle and optimized heat treatment to enable better opening, improved vessel-wall apposition, and reduced manipulation during deployment. These enhancements address common procedural challenges physicians face in flow diversion, helping streamline deployment and build confidence in complex cases.

This blend of innovation and usability is echoed by others with firsthand experience and deep familiarity with the device.

“I have been fortunate to be part of the development of the Surpass Elite Flow Diverter, Stryker’s most sophisticated flow-diverting stent to date,” said Dr. Alex Coon, Carondelet Neurological Institute, Tucson, Arizona. “My early experience suggests that this device gives physicians the exact blend of device opening, vessel-wall apposition, and surface treatment for which we have all been waiting a decade.”

Surpass Elite Flow Diverter received FDA approval and CE Mark in 2024. Stryker implemented a measured rollout focused on physician training and real-world clinical validation before scaling commercially.

www.stryker.com